Table 3.

Anti-HBs seroprotection rates and geometric mean antibody titers one month post-dose 3 (ATP immunogenicity cohort).

			≥ 6.2 mIU/ml			≥ 10 mIU/ml			GMT
Group	Timing	N	n	%	(95% CI)	n	%	(95% CI)	value	(95% CI)
R	Screening	398	83	20.9	(17.0; 25.2)	63	15.8	(12.4; 19.8)	5.0	(4.5; 5.7)
	Post-III	397	397	100	(99.1; 100)	397	100	(99.1; 100)	6412.7	(5732.9; 7173.0)
C	Screening	251	57	22.7	(17.7; 28.4)	45	17.9	(13.4; 23.2)	5.4	(4.7; 6.4)
	Post-III	253	246	97.2	(94.4; 98.9)	243	96.0	(92.9; 98.1)	377.4	(310.6; 458.7)

Group R = All study groups that received RTS,S/AS01 vaccine.

Group C = All study groups that received HBV vaccine.

N = number of subjects with available results.

GMT = geometric mean antibody titer calculated on all subjects.

n/% = number/percentage of subjects with titer ≥ specified value.

95% CI = 95% confidence interval.

Screening = Pre-vaccination, Post III = one month post-dose 3.

ATP = according to protocol.